产品专利是否合法合规 泰恩康创业板IPO注册阶段获问询

智通财经APP获悉，1月6日，证监会官网公布广东泰恩康医药股份有限公司（泰恩康）注册阶段问询问题。证监会就公司委托生产、风险因素信息披露、核心技术三方面进行问询。其中，证监会要求泰恩康说明已上市产品盐酸达泊西汀片及在研主要产品盐酸普拉克索缓释片、他达拉非片、奥硝唑注射液、阿加曲班注射液等的研发过程、技术来源、形成的相关专利，是否合法合规，是否存在争议或潜在纠纷。

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.